Mayukh Sukhatme, MD
About Mayukh Sukhatme, MD
Mayukh Sukhatme, MD: President & Chief Investment Officer
Mayukh Sukhatme, MD, currently holds the position of President and Chief Investment Officer at Roivant. In this role, he oversees the company's investment strategies and decisions, guiding the team in identifying and managing investment opportunities. His leadership is pivotal in steering the company's growth and ensuring it meets its strategic objectives.
Mayukh Sukhatme's Education and Expertise
Mayukh Sukhatme earned his M.D. from Harvard Medical School, a testament to his strong foundation in medical knowledge. He also holds dual Bachelor of Science degrees in Biology and Literature from MIT, reflecting his interdisciplinary academic interests. His diverse educational background underpins his comprehensive understanding of both medical and investment landscapes.
Mayukh Sukhatme's Career Background
Mayukh Sukhatme has an extensive career in the healthcare investment sector. Before joining Roivant in 2015, he worked from 2000 to 2015 as a healthcare-focused analyst and portfolio manager for multiple large institutional investment firms. His experience spans public markets and venture capital firms, providing him with a broad perspective on investment strategies and market dynamics.
Mayukh Sukhatme's Roles at Roivant
At Roivant, Mayukh Sukhatme has held several key positions. Before becoming President and Chief Investment Officer, he served as President of Roivant Pharma and Chief Business Officer. In these roles, he was instrumental in leading diligence and making investment decisions across various companies and pharmaceutical compounds, covering a wide range of therapeutic areas.
Investment Leadership of Mayukh Sukhatme
Mayukh Sukhatme has significant experience leading diligence and investment decisions in the healthcare sector. His expertise spans various therapeutic areas and involves evaluating numerous companies and pharmaceutical compounds. This deep experience positions him effectively to drive strategic investments and foster Roivant's growth in the competitive healthcare market.